NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) Dividend History

NewAmsterdam Pharma Company N.V. is a biopharmaceutical company focused on discovering and developing innovative therapies for cardiovascular diseases. Established with a research-oriented approach, it aims to address unmet medical needs through advanced science and targeted treatments. The company is listed on the stock exchange under the ticker NAMS and operates with a focus on improving patient outcomes in the cardiovascular space.

Gooimeer 2-35, Narrden, P7, 1411 DC
Phone: 35 206 2971
Website: https://www.newamsterdampharma.com

Dividend History

NewAmsterdam Pharma Company N.V. Ordinary Shares currently does not pay dividends

Company News

  • NewAmsterdam Pharma announced positive results from a pre-specified Alzheimer's disease biomarker analysis in its Phase 3 BROADWAY trial, showing statistically significant reductions in key biomarkers in both the full study population and in ApoE4 carriers. The findings support the potential of obicetrapib, a CETP inhibitor, to prevent Alzheimer's disease progression.

    GlobeNewswire Inc.
  • NewAmsterdam (NAMS) gains on the initiation of a phase III study evaluating fixed-dose combination of obicetrapib and ezetimibe in patients with HeFH and/or ASCVD.

    Zacks Investment Research
    Featured Companies: ADMA FGEN REGN
  • Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode Therapeutics shares dipped 24.3% to $0.8248 on Friday. Here are some other stocks moving in today's mid-day session. Gainers Charge Enterprises, Inc. (NASDAQ: CRGE) shares surged 105.4% to $0.2510. Kaman Corporation (NASDAQ: KAMN) shares climbed 101.3% to $45.14 after the company announced it will be acquired by Arcline for $1.8 billion. Mesa Air Group Inc (NASDAQ: MESA) gained 70.4% to $1.09 as the company entered into new agreements with United Airlines for improved operating and financing terms. Edgewise Therapeutics, Inc. (NASDAQ: EWTX) rose 37.3% to $13.30 after the company announced pricing of its $240 million underwritten offering of 21,818,182 shares at $11 per share. Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) climbed 34.2% to $0.2725. Processa Pharmaceuticals announced plans to expand the development of next generation capecitabine (NGC-Cap) into advanced or metastatic breast cancer beginning with next Phase 2 trial in breast cancer. Tricon Residential Inc. (NYSE: TCN) shares gained 28.2% to $11.06 Blackstone and Tricon Residential entered into an arrangement agreement under which Blackstone Real Estate Partners X together with Blackstone Real Estate Income Trust, Inc. will acquire all outstanding common shares of Tricon for $11.25 per share in cash. Spirit Airlines, Inc. (NYSE: SAVE) jumped 24% to $7.06 after the company announced preliminary fourth-quarter and full year 2023 estimates, issued first-quarter 2024 guidance and said the merger agreement between the company and JetBlue "remains in full force and effect." Super Micro Computer, Inc. (NASDAQ: SMCI) climbed 23.1% to $383.31 after the company announced updated financial guidance for the second-quarter, which surpassed its previous outlook. Allied Gaming & Entertainment Inc. (NASDAQ: AGAE) rose 20.6% to $1.1190. Portage Biotech Inc. (NASDAQ: PRTG) gained 19% to $1.14. ProMIS Neurosciences, Inc. (NASDAQ: PMN) ...

    Benzinga
  • The company announced a stock sale to help fund operations.

    The Motley Fool
Page data last updated 07/23/2025 16:12:30 UTC